Obesity, Cancer Risk, and Time-restricted Eating
Overview
Authors
Affiliations
Obesity and the associated metabolic syndrome is considered a pandemic whose prevalence is steadily increasing in many countries worldwide. It is a complex, dynamic, and multifactorial disorder that presages the development of several metabolic, cardiovascular, and neurodegenerative diseases, and increases the risk of cancer. In patients with newly diagnosed cancer, obesity worsens prognosis, increasing the risk of recurrence and decreasing survival. The multiple negative effects of obesity on cancer outcomes are substantial, and of great clinical importance. Strategies for weight control have potential utility for both prevention efforts and enhancing cancer outcomes. Presently, time-restricted eating (TRE) is a popular dietary intervention that involves limiting the consumption of calories to a specific window of time without any proscribed caloric restriction or alteration in dietary composition. As such, TRE is a sustainable long-term behavioral modification, when compared to other dietary interventions, and has shown many health benefits in animals and humans. The preliminary data regarding the effects of time-restricted feeding on cancer development and growth in animal models are promising but studies in humans are lacking. Interestingly, several short-term randomized clinical trials of TRE have shown favorable effects to reduce cancer risk factors; however, long-term trials of TRE have yet to investigate reductions in cancer incidence or outcomes in the general population. Few studies have been conducted in cancer populations, but a number are underway to examine the effect of TRE on cancer biology and recurrence. Given the simplicity, feasibility, and favorable metabolic improvements elicited by TRE in obese men and women, TRE may be useful in obese cancer patients and cancer survivors; however, the clinical implementation of TRE in the cancer setting will require greater in-depth investigation.
Nair P, Palanisamy A, Ramalakshmi R, Devibala M, Saranya M, Sivaranjini S Cureus. 2025; 17(1):e77005.
PMID: 39912042 PMC: 11797076. DOI: 10.7759/cureus.77005.
Habitual sleep duration, healthy eating, and digestive system cancer mortality.
Noga D, Meth E, Pacheco A, Cedernaes J, Xue P, Benedict C BMC Med. 2025; 23(1):44.
PMID: 39865237 PMC: 11770963. DOI: 10.1186/s12916-025-03882-w.
Han Y, Ye S, Liu B Front Endocrinol (Lausanne). 2024; 15:1409000.
PMID: 39268243 PMC: 11390393. DOI: 10.3389/fendo.2024.1409000.
Research advances in the therapy of metabolic syndrome.
Lin Z, Sun L Front Pharmacol. 2024; 15:1364881.
PMID: 39139641 PMC: 11319131. DOI: 10.3389/fphar.2024.1364881.
Female obesity: clinical and psychological assessment toward the best treatment.
Guglielmi V, Dalle Grave R, Leonetti F, Solini A Front Endocrinol (Lausanne). 2024; 15:1349794.
PMID: 38765954 PMC: 11099266. DOI: 10.3389/fendo.2024.1349794.